TY - JOUR AU - Smith, Katherine R. AU - Suppiah, Vijayaprakash AU - O'Connor, Kate AU - Berg, Thomas AU - Weltman, Martin AU - Abate, Maria Lorena AU - Spengler, Ulrich AU - Bassendine, Margaret AU - Matthews, Gail AU - Irving, William L. AU - Powell, Elizabeth AU - Riordan, Stephen AU - Ahlenstiel, Golo AU - Stewart, Graeme J. AU - Bahlo, Melanie AU - George, Jacob AU - Booth, David R. AU - the International Hepatitis C Genetics Consortium (IHCGC) PY - 2011 DA - 2011/08/31 TI - Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort JO - Genome Medicine SP - 57 VL - 3 IS - 8 AB - The hepatitis C virus (HCV) infects nearly 3% of the World's population, causing severe liver disease in many. Standard of care therapy is currently pegylated interferon alpha and ribavirin (PegIFN/R), which is effective in less than half of those infected with the most common viral genotype. Two IL28B single nucleotide polymorphisms (SNPs), rs8099917 and rs12979860, predict response to (PegIFN/R) therapy in treatment of HCV infection. These SNPs were identified in genome wide analyses using Illumina genotyping chips. In people of European ancestry, there are 6 common (more than 1%) haplotypes for IL28B, one tagged by the rs8099917 minor allele, four tagged by rs12979860. SN - 1756-994X UR - https://doi.org/10.1186/gm273 DO - 10.1186/gm273 ID - Smith2011 ER -